arrow
A

Austin I. Kim

dana-farber cancer institute
H指数:15
被引数:967

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL

安全加速Venetoclax剂量递增:一项obinutuzumab联合Venetoclax每日递增剂量方案在CLL中的1b期研究

2026-06-250
OA
A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation

一项Duvelisib联合Venetoclax在复发/难治性CLL/SLL或Richter转化的患者中的I/II期研究

2026-03-300
OAAI
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma

整合单细胞生物物理和转录组特征以解析套细胞淋巴瘤的功能异质性

2025-12-050
OA
Long-Term Follow-up of Bendamustine/Rituximab- Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

bendamustine/Rituximab- Rituximab/Cytarabine (BR/RC)诱导治疗对先前未治疗的移植符合条件的套细胞淋巴瘤(MCL)患者的长期随访

BLOOD
IF23.1
2024-11-050
PRE
Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

伊匹木单抗联合或不联合纳武利尤单抗治疗PD-1阻断治疗后进展的经典型霍奇金淋巴瘤患者

BLOOD
IF23.1
2024-11-050
PRE
A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

一项关于杜维利昔布和维奈克拉在复发或难治性(R/R)慢性淋巴细胞白血病(CLL)或里奇综合征(RS)患者中的2期研究

BLOOD
IF23.1
2024-11-052
PRE
Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

I期/II期研究中Acalabrutinib、Venetoclax和Obinutuzumab在复发/难治性及初治套细胞淋巴瘤患者中的初步疗效与安全性(MAVO)

BLOOD
IF23.1
2024-11-050
PRE
Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

双难治性(DR)或双暴露(DE) CLL患者的特征与结局

BLOOD
IF23.1
2024-11-050
PRE
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
2023-10-184
PRE
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
2023-08-236
OAAI
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction The STOP-CA Randomized Clinical Trial
2023-08-0859
OA
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
2023-02-010
OAAI
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma

淋巴瘤患者接受或不接受派姆单抗维持治疗的大剂量化疗和自体干细胞移植后的免疫重建

2022-01-019
OAAI
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
2020-01-0952
OA